ABIO:NSD-ARCA biopharma, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.50

Change

+0.06 (+1.74)%

Market Cap

USD 0.05B

Volume

0.23M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Company Website : http://www.arcabio.com

Address : 10170 Church Ranch Way, Westminster, CO, United States, 80021

Employees : 11

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.78

52 Week High : 10.25

Short Ratio : 0.57

52 Week Low : 3.20

Shorted Shares : 471,152

200 Day Moving Average : 4.19

Shorted Shares Previous Month : 324,708

50 Day Moving Average : 3.84

Shares Held By Insiders : 2.58%

Short Percentage : 3.00%

Shares Held by Institutions : 5.7%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-1.40 (-0.83%)

 USD66.76B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-3.78 (-1.72%)

 USD56.88B 21.36 15.53
REGN Regeneron Pharmaceuticals, Inc

-16.05 (-3.17%)

 USD54.26B 16.60 12.83
BNTX BioNTech SE

+7.15 (+4.42%)

 USD37.72B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

-0.79 (-0.47%)

 USD37.13B 61.79 35.79
BGNE BeiGene, Ltd

+9.06 (+3.00%)

 USD28.73B N/A N/A
SGEN Seagen Inc

-3.84 (-2.60%)

 USD26.74B 43.77 35.78
RPRX Royalty Pharma plc

+0.43 (+1.01%)

 USD25.97B 22.60 15.19
GMAB Genmab A/S

+0.28 (+0.77%)

 USD23.74B 26.59 3.37
CVAC CureVac N.V

+1.16 (+1.03%)

 USD20.99B N/A N/A

ETFs Containing ABIO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.72% 33% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.72% 33% F 16% F
Trailing 12 Months  
Capital Gain -15.25% 28% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.25% 27% F 8% F
Trailing 5 Years  
Capital Gain -94.64% 11% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -94.64% 11% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -37.77% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.77% 3% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 29.41% 88% B+ 58% F
Risk Adjusted Return -128.46% 1% F N/A N/A
Market Capitalization 0.05B 7% F 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.76 34% F 55% F
Price/Book Ratio 1.04 98% A+ 88% B+
Price / Cash Flow Ratio -6.42 44% F 71% C-
EV/EBITDA 0.03 92% A- 98% A+
Management Effectiveness  
Return on Equity -35.98% 72% C- 29% F
Return on Invested Capital -36.05% 64% D 21% F
Return on Assets -20.70% 62% D- 19% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.57 85% B 77% C+
Short Percent 3.28% 75% C 51% F
Beta 2.78 5% F 4% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.